BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed TAK catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:93ae2e1696fefea94c3a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK P2 readout (est.): A Study of TAK-360 in Adults With Idiopathic
  Hypersomnia
DESCRIPTION:A Study of TAK-360 in Adults With Idiopathic Hypersomnia\nNCT06
 812078 | PHASE2 | RECRUITING | sponsor: Takeda\nPrimary completion date (E
 STIMATED)\; top-line results usually follow later.\nTicker TAK (confidence
  0.9)\nSource: https://clinicaltrials.gov/study/NCT06812078\nScheduling/re
 ference data from public records\; dates can move. Not investment\, legal 
 or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06812078
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:3b255bf0ca27963550bf@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK P2 readout (est.): A Study of TAK-360 in Adults With Narcolepsy
  Without Cataplexy (NT2)
DESCRIPTION:A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy 
 (NT2)\nNCT06952699 | PHASE2 | RECRUITING | sponsor: Takeda\nPrimary comple
 tion date (ESTIMATED)\; top-line results usually follow later.\nTicker TAK
  (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06952699\nS
 cheduling/reference data from public records\; dates can move. Not investm
 ent\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06952699
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:5706de3fb54b2e0f8981@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:TAK P3 readout (est.): A Trial of TAK-861 for the Treatment of Narc
 olepsy With Cataplexy
DESCRIPTION:A Trial of TAK-861 for the Treatment of Narcolepsy With Cataple
 xy\nNCT07363720 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Takeda\nPrimar
 y completion date (ESTIMATED)\; top-line results usually follow later.\nTi
 cker TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT073
 63720\nScheduling/reference data from public records\; dates can move. Not
  investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07363720
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:1b7e1d97f0940c50819c@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:TAK P3 readout (est.): A Study to Evaluate the Safety and Tolerabil
 ity\, Pharmacokinetics\, and Antiviral Activity of Maribavir for the Treat
 ment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Ha
 ve Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ T
 ransplant (SOT)
DESCRIPTION:A Study to Evaluate the Safety and Tolerability\, Pharmacokinet
 ics\, and Antiviral Activity of Maribavir for the Treatment of Cytomegalov
 irus (CMV) Infection in Children and Adolescents Who Have Received a Hemat
 opoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)\nNC
 T05319353 | PHASE3 | RECRUITING | sponsor: Takeda\nPrimary completion date
  (ESTIMATED)\; top-line results usually follow later.\nTicker TAK (confide
 nce 0.9)\nSource: https://clinicaltrials.gov/study/NCT05319353\nScheduling
 /reference data from public records\; dates can move. Not investment\, leg
 al or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05319353
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6a4b33593894ecbcdad1@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:TAK P2 readout (est.): A Study of Zasocitinib in Adults With Hidrad
 enitis Suppurativa
DESCRIPTION:A Study of Zasocitinib in Adults With Hidradenitis Suppurativa\
 nNCT07244263 | PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Takeda\nPrimary c
 ompletion date (ESTIMATED)\; top-line results usually follow later.\nTicke
 r TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT072442
 63\nScheduling/reference data from public records\; dates can move. Not in
 vestment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07244263
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:9daab703f82916dfc778@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:TAK P3 readout (est.): A Study of Teduglutide in Chinese Adults Wit
 h Short Bowel Syndrome
DESCRIPTION:A Study of Teduglutide in Chinese Adults With Short Bowel Syndr
 ome\nNCT06973304 | PHASE3 | ACTIVE_NOT_RECRUITING | sponsor: Takeda\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06
 973304\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06973304
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e4ba6eb5f7e8d50cfe63@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:TAK P2 readout (est.): A Study on the Safety of TAK-279 and Whether
  it Can Reduce Inflammation in the Bowel of Participants With Moderately t
 o Severely Active Crohn's Disease
DESCRIPTION:A Study on the Safety of TAK-279 and Whether it Can Reduce Infl
 ammation in the Bowel of Participants With Moderately to Severely Active C
 rohn's Disease\nNCT06233461 | PHASE2 | RECRUITING | sponsor: Takeda\nPrima
 ry completion date (ESTIMATED)\; top-line results usually follow later.\nT
 icker TAK (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06
 233461\nScheduling/reference data from public records\; dates can move. No
 t investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06233461
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d231270d89944eaf7f57@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260828
DTEND;VALUE=DATE:20260829
SUMMARY:TAK APPROVAL: MIMRYLO
DESCRIPTION:Approved 2026-08-28: MIMRYLO (NDA220605 ORIG1)\nConfidence: con
 firmed\nTicker TAK (confidence 0.6)\nSource: https://www.accessdata.fda.go
 v/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220605\nSchedul
 ing/reference data from public records\; dates can move. Not investment\, 
 legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220605
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:1a55b1c8a3bad1fb3e36@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260805
DTEND;VALUE=DATE:20260806
SUMMARY:TAK APPROVAL: ORZEYFUL
DESCRIPTION:Approved 2026-08-05: ORZEYFUL (NDA220860 ORIG1)\nConfidence: co
 nfirmed\nTicker TAK (confidence 0.6)\nSource: https://www.accessdata.fda.g
 ov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220860\nSchedu
 ling/reference data from public records\; dates can move. Not investment\,
  legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=220860
CATEGORIES:approval,confirmed
END:VEVENT
BEGIN:VEVENT
UID:173435922bd14eb7000f@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20251121
DTEND;VALUE=DATE:20251122
SUMMARY:TAK APPROVAL: LIVTENCITY
DESCRIPTION:Approved 2025-11-21: LIVTENCITY (NDA215596 SUPPL7)\nConfidence:
  confirmed\nTicker TAK (confidence 0.6)\nSource: https://www.accessdata.fd
 a.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215596\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=215596
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
